ProShares Ultra NASDAQ Biotechnology
BIB
BIB
26 hedge funds and large institutions have $22.9M invested in ProShares Ultra NASDAQ Biotechnology in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
8.44% more ownership
Funds ownership: 3.51% → 11.94% (+8.4%)
4% more funds holding
Funds holding: 25 → 26 (+1)
Holders
26
Holding in Top 10
–
Calls
$5.02M
Puts
$3.93M
Top Buyers
| 1 | +$6.34M | |
| 2 | +$3.68M | |
| 3 | +$2.25M | |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$1.54M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.02M |
Top Sellers
| 1 | -$1.97M | |
| 2 | -$113K | |
| 3 | -$60.9K | |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$49K |
| 5 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$35K |